APRE Insider Trading Activity and SEC Form 4 Filings
APRE insider trading summary
Over the past 12 months, insiders at Aprea Therapeutics, Inc. (APRE) reported 4 open-market purchases worth $61K by 3 insiders and no sales on SEC Form 4. Net insider buying was $61K.
Latest APRE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 30, 2026 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | $5K (5,700 @ $0.89) |
| Jan 30, 2026 | Oren Gilad | President/CEO | Buy | $25K (28,100 @ $0.89) |
| Dec 10, 2025 | John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | $6K (5,000 @ $1.17) |
| Dec 10, 2025 | Marc Duey | Director | Buy | $25K (21,459 @ $1.17) |
| Apr 3, 2025 | Oren Gilad | President/CEO | Buy | $6K (3,003 @ $1.87) |
| Apr 3, 2025 | Oren Gilad | President/CEO | Buy | $4K (2,497 @ $1.80) |
| Oct 23, 2024 | Oren Gilad | President/CEO | Buy | $2K (500 @ $3.92) |
| Oct 18, 2024 | Marc Duey | Director | Sell | $30K (6,462 @ $4.58) |
| Oct 16, 2024 | Marc Duey | Director | Buy | $132K (30,000 @ $4.39) |
| Oct 15, 2024 | Oren Gilad | President/CEO | Buy | $725 (250 @ $2.90) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.